(Sharecast News) - Drugmaker GSK said on Wednesday that China's National Medical Products Administration has approved Exdensur as an add‑on therapy with intranasal corticosteroids for adults with chronic rhinosinusitis with nasal polyps who do not achieve adequate control with systemic steroids or surgery.
GSK noted that the NMPA's decision follows its...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE